-
Article | 2021.08.18
Your subscription is now complete
Thank your for your interest.You are now signed up for the Institut Pasteur newsletter.You will receive it once a month.You can easily unsubscribe at any moment by using the unsubscribe link that appears in each email.If you do not receive this email, please check your spam, bulk email folder or promotions tab in gmail.Institut Pasteur
-
Article | 2021.08.18
Your subscription is almost complete
Thank you for signing up for the Institut Pasteur newsletter.You will soon receive an email asking you to confirm this subscription.If you don’t receive this email, we suggest you check in your spam folder.Institut Pasteur
-
Page avancée | 2021.08.23
The Institut Pasteur Newsletter
Every month, all the scientific and institutional news of the Institut Pasteur: news, press releases, reports...
-
Document de presse | 2021.08.19
Immune checkpoint inhibitors improve cellular immunity against SARS-CoV-2
Researchers and doctors from the AP-HP, the Institut Pasteur, the University of Paris and the Sorbonne University, have carried out work on the effect of immune checkpoint inhibitors (anti-PD1 and anti-CTLA4) on cellular immunity against SARS-CoV-2. This work, the results of which suggest that these treatments are not deleterious during infection with COVID-19 and, on the contrary, seem to...
-
Document de presse | 2021.08.26
COVID-19: Will telecommuting strategies stop the virus from circulating?
How can we best organise on-site workplace and school attendance periods and remote work to slow the circulation of Sars-CoV-2? Is it better to separate classes? Bring your whole team in at the same time? Set this up on daily or weekly schedules? The COVID-19 pandemic has forced most countries to impose contact limitations in workplaces, universities and schools. Scientists from the CNRS,...
-
Fiche maladie | 2015.10.06
Candidiasis
Fungi (yeast) of the Candida genus can cause superficial infections affecting the mucous membranes or skin, and invasive infections, either localized to one organ or generalized throughout the body. Of the 200 known species of Candida, around twenty are responsible for human infection. Candida yeasts are often responsible for severe, hospital-acquired infections.
-
News | 2021.07.23
A new method for identifying differences between bacterial strains from the same environment
In recent years, the scientific community has realized that different bacterial strains can play very different roles in an environment. The identification of these strains and their genomes is important for both basic research and human health. Scientists from the Institut Pasteur have developed a method to identify the genomes of different strains in the same environment.For any given type of...
-
News | 2021.08.19
Monkeypox in Central African Republic: genomic history suggests multiple introductions from rainforest animal reservoirs
Monkeypox is an emerging and neglected infectious disease caused by the Monkeypox virus (MPXV). The disease has a similar clinical presentation to smallpox, with a maculopapular rash (a skin rash characterized by small spots), especially on the palms of the hands and the soles of the feet.Human transmission of the MPXV virus, responsible for monkeypox, occurs either through direct contact with...
-
News | 2021.09.02
Use of bacteriophages for preventing the most common foodborne infection, salmonellosis
Salmonellosis caused by the Salmonella bacterium is the most common example of foodborne infections, which remain a global public health problem, with over 600 million infections and 400,000 deaths every year. Use of antibiotics during outbreaks entails a risk of resistance. Scientists at the Institut Pasteur have demonstrated that bacteriophages may be used as a prophylactic treatment.The...
-
News | 2021.09.09
SPKM001, a promising anti-SARS-CoV-2 monoclonal antibody, is being developed by the Institut Pasteur and SpikImm
Following encouraging initial results, which will be published shortly, the Institut Pasteur and SpikImm announce the development of the antibody SPKM001.Paris, September 9, 2021SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the Spike protein of the original SARS-CoV-2 strain and its variants.Initial preclinical results tend to show that this...
